Care through discovery
Our multi-disciplinary teams of basic and translational, clinical, and health services scientists work with cutting-edge technology platforms in an environment that strives for innovation, creativity and new ways of thinking.
Research at the Paul Albrechtsen Research Institute CancerCare Manitoba is informed by everyday clinical challenges faced by Manitoba oncologists, and our overriding goal is to positively impact the lives of cancer patients and their families.
Clinical Trials
Tomorrow's treatment today
Clinical trials, research studies that test a medical intervention in people, are essential to advancing cancer care and the primary way scientists determine if a new form of detection, treatment, or support offers advantages over the current standard.
Each year about 300 Manitoban cancer patients are enrolled in approximately 120 clinical trials at CCMB, while thousands remain in long-term follow-up.
The Manitoba Tomorrow Project
Let’s change the course of cancer
The Manitoba Tomorrow Project is part of a 50-year nationwide research initiative, one of the largest studies ever undertaken to advance our knowledge about cancer and other chronic diseases – and you can help!
We need people ages
30-74 to sign up.
Research News
May 16, 2024
New book from Institute researcher, Dignity in Care: The Human Side of Medicine helps shape the future of patient care
Senior Scientist at CancerCare Manitoba Research Institute, Dr. Harvey Max Chochinov has published a new book, Dignity in Care: The Human Side of Medicine, providing insight into how the disposition and attitude of healthcare providers indelibly shape patient experience.
May 16, 2024
New trial looks at reducing bleeding risk in cancer patients while also developing novel research methods
A new Investigator-Initiated Clinical Trial (IICT) led by Primary Investigator, Dr. Brett Houston, called the MYELO-CAN TXA trial, aims to see whether Tranexamic Acid (TXA) can help prevent bleeding in patients with certain blood cancers such as acute leukemia and myelodysplastic syndrome.
May 16, 2024
Advanced magnetic resonance simulator to bring new options for research and treatment
The Institute has acquired a state-of-the-art magnetic resonance simulator (MR-SIM) to be installed in 2024, made possible by generous community donations. The research applications of this technology will include new patient treatment techniques and workflows.
;
Kicking off the 2024 Provincial #CancerCare Conference! Dr. Biniam Kidane’s keynote at the 2024 Provincial Cancer Care Conference was a highlight! His powerful talk on Endoscopic Submucosal Dissection (#ESD) & how #patientstories inspire innovation.
Congrats to Dr. Mark Nachtigal @CancerCareMB @umanitoba on receiving a $130K #CancerResearch Society grant, co-funded by #OvarianCancer Canada! His innovative study will explore a new glycolipid drug to target chemo-resistant ovarian cancer cells. Exciting progress ahead!
Congrats to Dr. Tanveer Sharif @CancerCareMB @umanitoba on his $130K #CancerResearch Society grant, in partnership with the Brain Canada Foundation! His "Precision Metabolism" project will explore metabolic pathways in therapy-resistant recurrent glioblastoma. #BrainCancer
Congrats to Dr. Sachin Katyal @1sachinkatyal @CancerCareMB @umanitoba on receiving a $130K Cancer Research Society grant! His work focuses on XRCC1 as a new biomarker & therapeutic target for treatment-resistant Glioblastoma Multiforme. #CancerResearch #Glioblastoma
It was my pleasure to share with the Minister of Economic Development, Hon. J. Moses, the unique work by the #CLL unit to improve the care of Manitobans, attract clinical and scientific research talent and partnerships MB. Thanks @abbviecanada for bringing our work visibility!
Proud moment for CancerCare Manitoba! Dr. Sachin Katyal. @1sachinkatyal represented us at the Marathon of Hope event in Ottawa, advocating for precision oncology. He shared our vision with MPs on improving outcomes for patients!
#TerryFox
